FDA grants priority tag to Bayer's oncology drug for first-line NSCLC
- Posted on May 19, 2026
- By Bing News
- 0 Views
- 1 min read
FDA grants priority tag to Bayer's oncology drug for first-line NSCLC
Bayer BAYRY announced that the FDA has granted priority review to sevabertinib for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have HER2 (ERBB2) tyrosine kinase domain (TKD)-activating mutations. Sevabertinib is a new oral, reversible small-molecule tyrosine kinase inhibitor (TKI) designed to selectively target mutant HER2, including HER2 exon 20 insertion and...
